Desvenlafaxine Succinate Tablet, Film Coated, Extended Release
Product Images NDC 50090-6894

9 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine Succinate (NDC 50090-6894). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (748a4941 405f 436f 933b 0bec4b119e3c 01)

Image (748a4941 405f 436f 933b 0bec4b119e3c 01)
Chemical structure of Desvenlafaxine Succinate, showing the molecular arrangement of its atoms including aromatic rings, hydroxyl groups, and succinate moiety with associated hydrate (H2O).*
FDA Label Image

Image (748a4941 405f 436f 933b 0bec4b119e3c 02)

Image (748a4941 405f 436f 933b 0bec4b119e3c 02)
A scientific figure titled 'Impact of Intrinsic Factors (Renal, Hepatic Impairment and Population Description) on Desvenlafaxine Pharmacokinetics' showing geometric mean ratios with 90% confidence intervals for Cmax and AUC of Desvenlafaxine under varying conditions. The chart compares mild, moderate, severe, and ESRD renal impairment and mild to severe hepatic impairment, plus population factors such as gender (females) and age groups (65-75 years and over 75 years). The x-axis indicates change relative to reference values.*
FDA Label Image

Image (748a4941 405f 436f 933b 0bec4b119e3c 03)

Image (748a4941 405f 436f 933b 0bec4b119e3c 03)
A pharmacokinetic bar graph showing the effect of CYP3A4 inhibitor Ketoconazole on Desvenlafaxine, with geometric mean ratios and 90% confidence intervals for Cmax and AUC values compared to reference, indicating changes relative to reference values from 0.5 to 2.0.*
FDA Label Image

Image (748a4941 405f 436f 933b 0bec4b119e3c 04)

Image (748a4941 405f 436f 933b 0bec4b119e3c 04)
A pharmacokinetic chart titled 'Effects of Desvenlafaxine on Pharmacokinetics of Other Drugs' showing geometric mean ratios with 90% confidence intervals for several drugs (Desipramine, Midazolam, Tamoxifen, and Aripiprazole) at different Desvenlafaxine dosages. The graph presents how Desvenlafaxine alters the Cmax and AUC parameters of these interacting drugs relative to reference values.*
FDA Label Image

Image (748a4941 405f 436f 933b 0bec4b119e3c 05)

Image (748a4941 405f 436f 933b 0bec4b119e3c 05)
A line graph titled 'Estimated Proportion of Relapses vs. Number of Days since Randomization (Study 5)' showing the estimated proportion of patients with relapse (%) on the y-axis and time to relapse (days from randomization) on the x-axis. It compares two groups: Desvenlafaxine extended-release tablets 50 mg (solid line) and placebo (dashed line), with relapse proportion increasing over time for both, but lower for the Desvenlafaxine group throughout.*
FDA Label Image

Image (748a4941 405f 436f 933b 0bec4b119e3c 06)

Image (748a4941 405f 436f 933b 0bec4b119e3c 06)
A Kaplan-Meier curve showing the estimated proportion of patients with relapse (%) over time in days from randomization. The graph compares Desvenlafaxine extended-release tablets with placebo, illustrating relapse rates over a period of up to approximately 180 days.*
FDA Label Image

Image (8c54cb6e C89e 4613 81f3 Cd24467fd163 1166 1)

Image (8c54cb6e C89e 4613 81f3 Cd24467fd163 1166 1)
Desvenlafaxine Succinate 50 mg film-coated extended-release tablet. The image shows a tablet shaped with an embossed pattern of a stylized flower or star design consisting of six petals or points. The tablet appears white and round, suitable for oral administration. No additional text or markings are visible on the tablet surface.*
FDA Label Image

Image (8c54cb6e C89e 4613 81f3 Cd24467fd163 1198 1)

Image (8c54cb6e C89e 4613 81f3 Cd24467fd163 1198 1)
Desvenlafaxine Succinate 50 mg extended-release film-coated tablets blister pack, showing a set of 10 oval white tablets arranged in two columns of five. The tablets are packaged in a transparent blister sealed with a silver foil backing. Labeled by A-S Medication Solutions.*
FDA Label Image

Label Image (Lbl500906894)

Label Image (Lbl500906894)
Desvenlafaxine Succinate 50 mg extended-release film-coated tablets label from A-S Medication Solutions. The label states each tablet contains 76 mg of Desvenlafaxine Succinate equivalent to 50 mg of the monohydrate, in a unit of use package with 30 tablets. Storage instructions indicate keeping at 20 to 25 degrees Celsius (controlled room temperature). The label includes the NDC 50090-6894-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.